Emerging strategy for the treatment of urothelial carcinoma : Advances in antibody-drug conjugates combination therapy
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system. Although there are various treatment modalities, including surgery, chemotherapy, and immune checkpoint inhibitor (ICI) therapy, some patients experience disease recurrence and metastasis with poor prognosis and dismal long-term survival. Antibody-drug conjugates (ADCs), which combine the targeting ability of antibody drugs with the cytotoxicity of chemotherapeutic drugs, have recently emerged as a prominent research focus in the development of individualized precision cancer therapy. Although ADCs have improved the overall response rate in patients with UC, their effectiveness remains limited. Currently, ADC-based combination therapies, particularly ADC combined with ICIs, have demonstrated promising efficacy. This combination approach has advanced the treatment of UC, exhibiting the potential to become the standard first-line therapy for advanced UC in the future. This article reviewed clinical trials involving ADC-based combination therapy for UC and discussed the possible challenges and future perspectives to provide guidance for the clinical treatment of UC.
| Errataetall: |
ErratumIn: Biomed Pharmacother. 2024 Mar 14;:116430. - PMID 38485617 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:171 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 171(2024) vom: 15. Feb., Seite 116152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
You, Xiangyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody–drug conjugates |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 14.03.2024 published: Print-Electronic ErratumIn: Biomed Pharmacother. 2024 Mar 14;:116430. - PMID 38485617 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116152 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36718589X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36718589X | ||
| 003 | DE-627 | ||
| 005 | 20240315233107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116152 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM36718589X | ||
| 035 | |a (NLM)38228034 | ||
| 035 | |a (PII)S0753-3322(24)00033-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a You, Xiangyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging strategy for the treatment of urothelial carcinoma |b Advances in antibody-drug conjugates combination therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Biomed Pharmacother. 2024 Mar 14;:116430. - PMID 38485617 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system. Although there are various treatment modalities, including surgery, chemotherapy, and immune checkpoint inhibitor (ICI) therapy, some patients experience disease recurrence and metastasis with poor prognosis and dismal long-term survival. Antibody-drug conjugates (ADCs), which combine the targeting ability of antibody drugs with the cytotoxicity of chemotherapeutic drugs, have recently emerged as a prominent research focus in the development of individualized precision cancer therapy. Although ADCs have improved the overall response rate in patients with UC, their effectiveness remains limited. Currently, ADC-based combination therapies, particularly ADC combined with ICIs, have demonstrated promising efficacy. This combination approach has advanced the treatment of UC, exhibiting the potential to become the standard first-line therapy for advanced UC in the future. This article reviewed clinical trials involving ADC-based combination therapy for UC and discussed the possible challenges and future perspectives to provide guidance for the clinical treatment of UC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibody–drug conjugates | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Urothelial carcinoma | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 700 | 1 | |a Zhu, Chunming |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Puguang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yibing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiahe |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Junfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kefeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 171(2024) vom: 15. Feb., Seite 116152 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:171 |g year:2024 |g day:15 |g month:02 |g pages:116152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116152 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 171 |j 2024 |b 15 |c 02 |h 116152 | ||